ProfileGDS5678 / 1453917_at
TitleAnti-VEGF and Anti-Notch treatment effect on U87 glioblastoma xenograft tumors [Mouse430_2]
OrganismMus musculus


control bevacizumab dibenzazepine GSM967852 GSM967853 GSM967854 GSM967855 GSM967856 GSM967862 GSM967863 GSM967864 GSM967865 GSM967857 GSM967858 GSM967859 GSM967860 GSM967861 28% 29% 29% 28% 29% 30% 46% 28% 29% 29% 28% 29% 28% 28% sort by agent Gene Expression Profile
Graph caption help
SampleTitleValueRank
GSM967852U87-EV human glioblastoma xenograft - Control 12.6663428
GSM967853U87-EV human glioblastoma xenograft - Control 22.6587529
GSM967854U87-EV human glioblastoma xenograft - Control 32.6574829
GSM967855U87-EV human glioblastoma xenograft - Control 42.5995228
GSM967856U87-EV human glioblastoma xenograft - Control 52.6078929
GSM967862U87-EV human glioblastoma xenograft - Bevacizumab treated 12.7491430
GSM967863U87-EV human glioblastoma xenograft - Bevacizumab treated 23.1598746
GSM967864U87-EV human glioblastoma xenograft - Bevacizumab treated 32.6324928
GSM967865U87-EV human glioblastoma xenograft - Bevacizumab treated 42.6284729
GSM967857U87-EV human glioblastoma xenograft - dibenzazepine treated 12.6465629
GSM967858U87-EV human glioblastoma xenograft - dibenzazepine treated 22.6348828
GSM967859U87-EV human glioblastoma xenograft - dibenzazepine treated 32.6363329
GSM967860U87-EV human glioblastoma xenograft - dibenzazepine treated 42.6506228
GSM967861U87-EV human glioblastoma xenograft - dibenzazepine treated 52.6418628